An interventional study of CCTA and Conventional ICA in Ischemic Heart Disease, Non STEMI and Angina Pectoris, Unstable, sponsored by Rigshospitalet, Denmark. Recruiting at 6 sites in Denmark. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment
Among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark — 3 open to participants now, 3 under way, none of them phase 3. Myocardial Ischemia · Rigshospitalet, Denmark.
Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 with no phase, and was the 13th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →3 of the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Rigshospitalet, Denmark · Sites in Denmark
By country, each count listing its studies:
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 1997; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2,300 is above the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 54 across the 12 interventional studies, 24 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,007 studies on the registry; 175 are open to participants now.
1 of the studies in Myocardial Ischemia by Rigshospitalet, Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06033014Rigshospitalet, DenmarkClinical Implementation of a Novel Decision Support Tool in Patients With Ischemic Heart Disease | 2026-12 |
Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).
If CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: CCTA · Other: Team-based interventional triage
Procedure: Conventional ICA
Participants will be examined with CCTA during admission.
Patients will be examined with conventional standard-of-care ICA.
The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
Number of participants with a combined endpoint of major adverse cardiac events
All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure.
Time frame: At 1 year.
Number of participants with a the individual composites of the primary outcome
All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure.
Time frame: At 1 year.
Number of participants with cardiovascular death
Time frame: At 1 year.
Number of participants with unplanned coronary revascularization
Time frame: At 1 year.
Health-related Quality of life
Measured by EQ-5D-5L
Time frame: At 1 year.
Angina symptom burden
Measured by Seattle Angina Questionnaire
Time frame: At 1 year.
Total (cumulative) radiation dosage during index admission
Time frame: At 1st hospital discharge, an average of 2 days.
Length of index hospitalization
Time frame: At 1st hospital discharge, an average of 2 days.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be shared upon reasonable request and uploaded to a repository after the trial has been concluded.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2026, 36 months after the start.
Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 36 months is close to that.
Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.